Inostics, a molecular diagnostics company that provides blood-based mutation testing, received CLIA (Clinical Laboratory Improvement Amendments) licensure for its clinical laboratory located in Baltimore, MD. This marks a critical milestone for the clinical adoption of this non-invasive molecular approach for the analysis of tumor biomarkers. "Due to the non-invasiveness and real-time reflection of tumor genetics, the OncoBEAM blood test represents a valuable tool to complement clinical decision making...
More...
More...